Skip to content

Released Nov 8, 2023, after the close

10-Q filed Nov 8, 2023, 39 days after period end · 0000950170-23-061080

Q3 2023 · 10-Q
Revenue$1.94M−87.0% vs Q3 2022+108.4% vs Q2 2023
Net Income-$45.17MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.46N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$51,279,000N/M
Operating Cash Flowderived-$38,273,000N/M
Free Cash Flowderived-$38,838,000N/M
Margins · derived
Operating margin-2637.8%−2061.1 pt vs Q3 2022
Net margin-2323.6%−1765.8 pt vs Q3 2022

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$1.94M$14.98M$14.23M$7.56M
Net Income-$45.17M-$83.56M-$43.31M-$58.68M
EPS Diluted-$0.46-$0.86-$0.45-$0.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR